Status:
COMPLETED
Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study
Lead Sponsor:
The University of Hong Kong
Conditions:
Exposure to Hepatitis B Virus
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis...
Detailed Description
Occult hepatitis B virus (HBV) reactivation has been documented in patients undergoing rituximab-containing chemotherapy who are hepatitis B surface antigen (HBsAg)-negative but with serologic evidenc...
Eligibility Criteria
Inclusion
- Documented HBsAg-negative with or without antibody to hepatitis B surface antigen (anti-HBs)
- Documented anti-HBc (total)-positive
Exclusion
- Concomitant liver diseases including chronic hepatitis C and D infection, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
- Significant alcohol intake (\>30 grams per day)
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01502397
Start Date
December 1 2011
End Date
March 1 2016
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, The University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong